galena biopharma originally rxi pharmaceuticals publicly traded pharmaceutical company based san ramon california company founded worcester massachusetts moved moved san ramon mark schwartz companys president chief executive december company acquired sellas life sciences group ltd reverse merger transaction galena biopharma renamed sellas life sciences group inc nasdaq november argonaut pharmaceuticals inc changed name rxi pharmaceuticals rxi subsidiary cytrx corp provided million financing april rxi founded part nobel prize winner craig september rxi signed licensing deal trilink biotechnologies competitor rna interference rnai field rxi would pay trilink use three trilinks march company announced planned acquisition arizonabased apthera inc million acquisition included breast cancer drug june neuvax approved united states food drug administration start stage three clinical september company separated cancer therapies division renamed galena biopharma inc moved lake oswego rxi became subsidiary galena retained rnai rxi pharmaceuticals remained massachusetts publicly traded january galena bought mills april company headquarters moved november company partnered genentech combine drugs company cancer galena currently studying combination neuvax herceptin phase ii march president ceo noah beerman replaced mark ahn august ahn resigned replaced mark january galena announced resignation mark schwartz effective day reported press release would exploring strategic alternatives maximize shareholder value going rxi went public march cytrx retained ownership rxis stock gave shares rxi existing shareholders trading began nasdaq market march ticker symbol fidelity investments invested million company may followed million privateequity investment yorkville february rxi received national institutes health grant august company april rxi raised million stock received grants national institutes company reported loss million loss november anonymous internet report caused galena stock decline company filed lawsuit claiming report false attempted manipulate galenas involvement fraudulent stock promotion scheme february analyst matt gravitt published article revealed galena paid missionir dreamteam brand promote galenas galenas stock fell following revelation received heated response one three read articles seeking alphas next weeks revelations came company admitted stock promotion relationship insider galena disclosed sec investigation relationship dreamteam march five lawsuits filed galena several officers alleging company used misleading articles boost stock motley fool discussing stock price drop march noted stock dilution offering also abstrals sales galenas estimates late discussing motley fool article portland business journal also noted ongoing insidertrading lawsuits factor stock days later zacks investment research said galena could great candidate beat response galenas ceo said many positive aspects company lawsuits werent worry get covered directors officers liability company moved san ramon california bay area revelation galena engaging fraudulent stock promotion without adequate disclosure led investigation biotech companies engaged similar activities richard pearson investor went undercover investigate stock promotion firms wrote expos√© dreamteam ties articles galena cytrx companies media april securities exchange commission announced enforcement actions individuals entities behind various alleged stock promotion schemes fraud charges filed three public companies seven stock promotion communications firms two company ceos also hit list six individuals nine galena biopharma inc announced merger privatelyheld oncology company sellas life sciences group ltd allstock combined company sellas life science group newly merged companies focused development novel treatments galena acquired experimental breast cancer drug neuvax currentlywhen phase ii trials combine drug genentechs galena began selling first developed drug analgesic cancer pain named abstral anagrelide controlledreleased approved fda phase iii clinical trials treatment essential thrombocytosis december immunotherapies phase ii trials ovarian breast httpsenwikipediaorgwikigalenabiopharma